PGR and neoplasm: Since the mid-1970s, pathological analysis of breast tumours, usually via IHC staining, has been used to determine the ER and progesterone receptor (PR) status of the tumor, with both markers having the ability to indicate the likelihood of recurrence and response to endocrine therapies [9].